To assess the long-term effects of DDX21 deficiency on proliferation and tumorigenesis, we utilized multiple shRNAs targeting endogenous human DDX21 to effectively knock down DDX21 protein expression in three highly proliferative breast cancer cell lines (Figure 4A). The gene discussed is DDX21; the disease is breast carcinoma.